Shares of Esperion (ESPR) Therapeutics are up 25c, or 19%, to $1.59 in afternoon trading. Traders have pointed to the circulation of rumors as a potential reason for the midday advance.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion signs settlement with Accord Healthcare over Nexletol generic version
- Esperion Expands Board with New Appointment
- Esperion appoints Craig Thompson to board of directors
- Esperion’s Strategic Growth and Global Expansion Drive Buy Rating
- Esperion participates in a conference call with Cantor Fitzgerald